These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 16391801)
21. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391 [TBL] [Abstract][Full Text] [Related]
22. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915 [TBL] [Abstract][Full Text] [Related]
23. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508 [TBL] [Abstract][Full Text] [Related]
24. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy. Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484 [TBL] [Abstract][Full Text] [Related]
25. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Bilsland AE; Anderson CJ; Fletcher-Monaghan AJ; McGregor F; Evans TR; Ganly I; Knox RJ; Plumb JA; Keith WN Oncogene; 2003 Jan; 22(3):370-80. PubMed ID: 12545158 [TBL] [Abstract][Full Text] [Related]
26. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy. Hay MP; Wilson WR; Denny WA Bioorg Med Chem; 2005 Jun; 13(12):4043-55. PubMed ID: 15911317 [TBL] [Abstract][Full Text] [Related]
27. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450 [TBL] [Abstract][Full Text] [Related]
28. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564 [TBL] [Abstract][Full Text] [Related]
29. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954. de Poorter JJ; Tolboom TC; Rabelink MJ; Pieterman E; Hoeben RC; Nelissen RG; Huizinga TW J Gene Med; 2005 Nov; 7(11):1421-8. PubMed ID: 15977303 [TBL] [Abstract][Full Text] [Related]
30. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy. Bailey SM; Knox RJ; Hobbs SM; Jenkins TC; Mauger AB; Melton RG; Burke PJ; Connors TA; Hart IR Gene Ther; 1996 Dec; 3(12):1143-50. PubMed ID: 8986441 [TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793 [TBL] [Abstract][Full Text] [Related]
32. Ablation of central nervous system progenitor cells in transgenic rats using bacterial nitroreductase system. Kwak SP; Malberg JE; Howland DS; Cheng KY; Su J; She Y; Fennell M; Ghavami A J Neurosci Res; 2007 May; 85(6):1183-93. PubMed ID: 17304579 [TBL] [Abstract][Full Text] [Related]
33. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Weedon SJ; Green NK; McNeish IA; Gilligan MG; Mautner V; Wrighton CJ; Mountain A; Young LS; Kerr DJ; Searle PF Int J Cancer; 2000 Jun; 86(6):848-54. PubMed ID: 10842200 [TBL] [Abstract][Full Text] [Related]
34. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510 [TBL] [Abstract][Full Text] [Related]
35. Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70. Djeha HA; Todryk SM; Pelech S; Wrighton CJ; Irvine AS; Mountain A; Lipinski KS Cancer Gene Ther; 2005 Jun; 12(6):560-71. PubMed ID: 15665820 [TBL] [Abstract][Full Text] [Related]
36. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Gautam A; Densmore CL; Melton S; Golunski E; Waldrep JC Cancer Gene Ther; 2002 Jan; 9(1):28-36. PubMed ID: 11916242 [TBL] [Abstract][Full Text] [Related]
37. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging. Sekar TV; Foygel K; Willmann JK; Paulmurugan R Gene Ther; 2013 May; 20(5):529-37. PubMed ID: 22914496 [TBL] [Abstract][Full Text] [Related]
38. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53. Lipinski KS; Djeha AH; Krausz E; Lane DP; Searle PF; Mountain A; Wrighton CJ Gene Ther; 2001 Feb; 8(4):274-81. PubMed ID: 11313801 [TBL] [Abstract][Full Text] [Related]